186 related articles for article (PubMed ID: 1637555)
41. Diagnostic utility of Müllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors.
Lane AH; Lee MM; Fuller AF; Kehas DJ; Donahoe PK; MacLaughlin DT
Gynecol Oncol; 1999 Apr; 73(1):51-5. PubMed ID: 10094880
[TBL] [Abstract][Full Text] [Related]
42. An immunoassay to detect human müllerian inhibiting substance in males and females during normal development.
Hudson PL; Dougas I; Donahoe PK; Cate RL; Epstein J; Pepinsky RB; MacLaughlin DT
J Clin Endocrinol Metab; 1990 Jan; 70(1):16-22. PubMed ID: 2294129
[TBL] [Abstract][Full Text] [Related]
43. Steroid modulation of Mullerian duct regression in the chick embryo.
Hutson JM; Donahoe PK; MacLaughlin DT
Gen Comp Endocrinol; 1985 Jan; 57(1):88-102. PubMed ID: 3838289
[TBL] [Abstract][Full Text] [Related]
44. Cyclic adenosine 3',5'-monophosphate modulation of mullerian duct regression.
Ikawa H; Hutson JM; Budzik GP; Donahoe PK
Endocrinology; 1984 May; 114(5):1686-91. PubMed ID: 6201348
[TBL] [Abstract][Full Text] [Related]
45. Developmentally regulated polyadenylation of two discrete messenger ribonucleic acids for müllerian inhibiting substance.
Lee MM; Cate RL; Donahoe PK; Waneck GL
Endocrinology; 1992 Feb; 130(2):847-53. PubMed ID: 1346380
[TBL] [Abstract][Full Text] [Related]
46. High specificity of Müllerian-inhibiting substance signaling in vivo.
Mishina Y; Whitworth DJ; Racine C; Behringer RR
Endocrinology; 1999 May; 140(5):2084-8. PubMed ID: 10218958
[TBL] [Abstract][Full Text] [Related]
47. Mullerian inhibiting substance: an update.
MacLaughlin DT; Donahoe PK
Adv Exp Med Biol; 2002; 511():25-38; discussion 38-40. PubMed ID: 12575754
[TBL] [Abstract][Full Text] [Related]
48. Müllerian inhibiting substance is present in embryonic testes of dogs with persistent müllerian duct syndrome.
Meyers-Wallen VN; Lee MM; Manganaro TF; Kuroda T; Maclaughlin D; Donahoe PK
Biol Reprod; 1993 Jun; 48(6):1410-8. PubMed ID: 8318594
[TBL] [Abstract][Full Text] [Related]
49. Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo.
Stephen AE; Masiakos PT; Segev DL; Vacanti JP; Donahoe PK; MacLaughlin DT
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3214-9. PubMed ID: 11248058
[TBL] [Abstract][Full Text] [Related]
50. The role of Müllerian inhibiting substance in the evaluation of phenotypic female patients with mild degrees of virilization.
Misra M; MacLaughlin DT; Donahoe PK; Lee MM
J Clin Endocrinol Metab; 2003 Feb; 88(2):787-92. PubMed ID: 12574214
[TBL] [Abstract][Full Text] [Related]
51. Measurement of Mullerian inhibiting substance facilitates management of boys with microphallus and cryptorchidism.
Misra M; MacLaughlin DT; Donahoe PK; Lee MM
J Clin Endocrinol Metab; 2002 Aug; 87(8):3598-602. PubMed ID: 12161481
[TBL] [Abstract][Full Text] [Related]
52. New insights into mullerian inhibiting substance and its mechanism of action.
Lane AH; Donahoe PK
J Endocrinol; 1998 Jul; 158(1):1-6. PubMed ID: 9713320
[TBL] [Abstract][Full Text] [Related]
53. Mullerian inhibiting substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-beta superfamily.
Wilson CA; di Clemente N; Ehrenfels C; Pepinsky RB; Josso N; Vigier B; Cate RL
Mol Endocrinol; 1993 Feb; 7(2):247-57. PubMed ID: 8469238
[TBL] [Abstract][Full Text] [Related]
54. Serum levels of mullerian inhibiting substance in boys throughout puberty and in the first two years of life.
Baker ML; Hutson JM
J Clin Endocrinol Metab; 1993 Jan; 76(1):245-7. PubMed ID: 8421093
[TBL] [Abstract][Full Text] [Related]
55. The ontogeny of Mullerian inhibiting substance in the gonads of the chicken.
Hutson J; Ikawa H; Donahoe PK
J Pediatr Surg; 1981 Dec; 16(6):822-7. PubMed ID: 6896069
[TBL] [Abstract][Full Text] [Related]
56. Müllerian inhibiting substance as oocyte meiosis inhibitor.
Takahashi M; Koide SS; Donahoe PK
Mol Cell Endocrinol; 1986 Oct; 47(3):225-34. PubMed ID: 2428679
[TBL] [Abstract][Full Text] [Related]
57. Androgen stimulation of nucleotide pyrophosphatase during mullerian duct regression.
Fallat ME; Hutson JM; Budzik GP; Donahoe PK
Endocrinology; 1984 May; 114(5):1592-8. PubMed ID: 6143657
[TBL] [Abstract][Full Text] [Related]
58. Antibody against avian müllerian inhibiting substance (MIS) recognizes MIS on rat müllerian duct and human tumor cells.
Wang JJ; Teng CS
Proc Natl Sci Counc Repub China B; 1989 Oct; 13(4):267-75. PubMed ID: 2484046
[TBL] [Abstract][Full Text] [Related]
59. Involvement of a matrix metalloproteinase in MIS-induced cell death during urogenital development.
Roberts LM; Visser JA; Ingraham HA
Development; 2002 Mar; 129(6):1487-96. PubMed ID: 11880357
[TBL] [Abstract][Full Text] [Related]
60. Müllerian inhibiting substance blocks epidermal growth factor receptor phosphorylation in fetal rat lung membranes.
Catlin EA; Uitvlugt ND; Donahoe PK; Powell DM; Hayashi M; MacLaughlin DT
Metabolism; 1991 Nov; 40(11):1178-84. PubMed ID: 1943746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
